Monday, October 5, 2026

Lego Smart Brick Claims Top Honor at CES 2026, Revolutionizing Toy Industry with AR and VR Features

The Lego Smart Brick wins Best in Show at CES 2026, combining classic building blocks with cutting-edge AR and VR technology to revolutionize interactive play.

LM Salvado

January 14, 2026

Lego Smart Brick Claims Top Honor at CES 2026, Revolutionizing Toy Industry with AR and VR Features
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Lego Smart Brick Wins Best in Show at CES 2026

The Lego Smart Brick took home the Best in Show award at CES 2026, marking a significant leap forward in the integration of technology and traditional toys. According to The Verge AI, the innovative product impressed attendees and judges alike with its advanced features and immersive capabilities.

The Lego Smart Brick, showcased by designer Maarten Simons, combines classic building blocks with modern smart technology. This unique blend aims to enhance the play experience by incorporating interactive elements and virtual reality (VR) features. The Verge AI's detailed report highlights the product's potential to revolutionize how children and adults interact with physical toys.

In an exclusive 15-minute demo, Maarten Simons demonstrated the capabilities of the Smart Brick, which include augmented reality (AR) overlays, voice recognition, and connectivity with other smart devices. The demo was captured using a specially modified Qoocam Q3 Ultra camera, capable of recording VR180 content. Viewers can experience the demo in a headset or through a flat-screen interface, providing an immersive look at the product's functionalities.

"The Lego Smart Brick is designed to bridge the gap between digital and physical play," said Maarten Simons. "We believe that combining the tactile experience of building with the interactive possibilities of smart technology can create a new level of engagement and creativity."

The integration of AR and VR technologies in the Smart Brick allows users to bring their creations to life in a virtual environment. For instance, a user can build a model car and then use an AR app to see it move around a virtual track. Additionally, the bricks can be programmed to respond to voice commands, enhancing the interactive experience.

The Verge AI's detailed coverage of the Smart Brick includes a comprehensive demonstration video, which viewers can access through various platforms, including YouTube and social media channels. The video provides an in-depth look at the product's features and showcases its potential applications.

With the Best in Show award, the Lego Smart Brick has positioned itself as a frontrunner in the evolving landscape of tech-infused toys. As technology continues to advance, products like the Smart Brick are likely to become more prevalent, offering new ways for users to engage with traditional toys in a digital age.

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com